MALVERN

TELA Bio Reports First Quarter 2024 Financial Results

Retrieved on: 
목요일, 5월 9, 2024

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024.
  • Q1 was a strong quarter and we believe the rest of 2024 will continue to showcase the progress TELA is delivering on key strategic priorities.”
    Revenue was $16.6 million in the first quarter of 2024, an increase of 39% compared to the same period in 2023.
  • Operating expenses were $23.7 million in the first quarter of 2024, compared to $19.2 million in the same period in 2023.
  • TELA Bio will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 9, 2024 to discuss its first quarter 2024 financial results.

Chris McDermott Joins Meridian Bank as SVP, Commercial Lending

Retrieved on: 
수요일, 5월 8, 2024

MALVERN, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Meridian Bank announced the appointment of Christopher E. McDermott to the position of Senior Vice President, Commercial Lending.

Key Points: 
  • MALVERN, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Meridian Bank announced the appointment of Christopher E. McDermott to the position of Senior Vice President, Commercial Lending.
  • He’ll join other members of the Meridian Commercial Lending Team in serving business customers in Bucks and Montgomery Counties.
  • He brings his breadth of expertise in establishing, building and leading commercial lending teams to his position at Meridian.
  • Meridian founder and CEO Chris Annas says he first met McDermott ten years ago, “And we’ve been trying to get him to join us ever since.

Vishay Intertechnology Space-Grade Planar Transformers Offer Lower Cost, Smaller Size, and Higher Density Than Traditional Planar Devices

Retrieved on: 
수요일, 5월 8, 2024

MALVERN, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc. (NYSE: VSH) today introduced a new series of low profile, space-grade planar transformers for power conversion applications.

Key Points: 
  • MALVERN, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc. (NYSE: VSH) today introduced a new series of low profile, space-grade planar transformers for power conversion applications.
  • Offering a lower cost, smaller size, and higher density than traditional planar transformers, customizable Vishay Custom Magnetics SGTPL-2516 series devices meet the requirements of MIL-STD-981 class S.
    Available with through-hole terminations and multiple package sizes, the devices released today will be used in switch mode power supplies and DC/DC and AC/DC converters.
  • Featuring a unique winding structure and build technique, the transformers provide a greater copper fill factor than can be achieved with traditional planar devices, resulting in a smaller package size and improved efficiency and power density.
  • Serving customers worldwide, Vishay is The DNA of tech.® Vishay Intertechnology, Inc. is a Fortune 1,000 Company listed on the NYSE (VSH).

Vishay Intertechnology Reports First Quarter 2024 Results

Retrieved on: 
수요일, 5월 8, 2024

MALVERN, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc., (NYSE: VSH), one of the world's largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal first quarter ended March 30, 2024.

Key Points: 
  • MALVERN, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc., (NYSE: VSH), one of the world's largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal first quarter ended March 30, 2024.
  • “As expected, first quarter revenue declined 5% sequentially primarily due to ongoing semiconductor inventory digestion and lingering macro-economic uncertainties, particularly in Asia and Europe.
  • Gross margin for the quarter included a 74-basis point negative impact from the addition of Newport,” said Joel Smejkal, President and Chief Executive Officer.
  • A conference call to discuss Vishay’s first quarter financial results is scheduled for Wednesday, May 8, 2024 at 9:00 a.m.

Neuronetics Reports Record First Quarter 2024 Financial and Operating Results

Retrieved on: 
화요일, 5월 7, 2024

In the first quarter of 2024, U.S. treatment session revenue per active site was $11,300 compared to $9,700 in the first quarter of 2023.

Key Points: 
  • In the first quarter of 2024, U.S. treatment session revenue per active site was $11,300 compared to $9,700 in the first quarter of 2023.
  • Operating expenses during the first quarter of 2024 were $19.9 million, a decrease of $1.4 million, or 7%, compared to $21.3 million in the first quarter of 2023.
  • Net loss for the first quarter of 2024 was $(7.9) million, or $(0.27) per share, as compared to $(10.5) million, or $(0.38) per share, in the first quarter of 2023.
  • EBITDA for the first quarter of 2024 was $(6.3) million as compared to the first quarter of 2023 EBITDA of $(9.4) million.

VPG Reports Fiscal 2024 First Quarter Results

Retrieved on: 
화요일, 5월 7, 2024

MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, today announced its results for its 2024 first fiscal quarter ended March 30, 2024.

Key Points: 
  • MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, today announced its results for its 2024 first fiscal quarter ended March 30, 2024.
  • First Fiscal Quarter Financial Trends:
    The Company's first fiscal quarter 2024 net earnings attributable to VPG stockholders were $5.9 million, or $0.44 per diluted share, compared to $7.0 million, or $0.51 per diluted share, in the three fiscal months ended April 1, 2023.
  • The Sensors segment revenue of $29.4 million in the first fiscal quarter of 2024 decreased 19.9% from $36.7 million in the first fiscal quarter of 2023, and decreased 14.1% compared to $34.3 million in the fourth fiscal quarter of 2023.
  • Gross profit margin for the Weighing Solutions segment was 39.1% for the first fiscal quarter of 2024, which increased compared to 34.9% in the first fiscal quarter of 2023, and increased compared to 35.6% in the fourth fiscal quarter of 2023.

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 5월 3, 2024

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 55,650 shares of the Company’s common stock (RSUs) to thirteen new non-executive employees.

Key Points: 
  • MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 55,650 shares of the Company’s common stock (RSUs) to thirteen new non-executive employees.
  • In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
  • Each of the RSU grants vests ratably in equal installments on the first, second, third and fourth anniversaries of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date.
  • The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.

Galera Adopts Limited Duration Stockholder Rights Agreement

Retrieved on: 
금요일, 5월 3, 2024

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests.

Key Points: 
  • MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests.
  • In addition, the Rights Agreement provides the Board with time to make informed decisions that are in the best long-term interests of Galera and its stockholders.
  • The Rights Agreement has an expiration date of May 2, 2025, and the Board will consider whether to terminate the Rights Agreement earlier than such date if warranted.
  • Except as provided in the Rights Agreement, the Board is entitled to redeem the rights at $0.001 per right.

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

Retrieved on: 
금요일, 5월 3, 2024

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2024 financial results and provide a business update at 8:30 a.m.

Key Points: 
  • MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2024 financial results and provide a business update at 8:30 a.m.
  • ET on Tuesday, May 14, 2024.
  • Ocugen will issue a pre-market earnings announcement on the same day.
  • Attendees are invited to participate on the call using the following details:

Frontline Flex Pay, Powered by Wagestream Now Available to All K-12 District Employees

Retrieved on: 
목요일, 5월 2, 2024

Malvern, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Frontline Education , a leading provider of administration software purpose-built for educators in K-12, today announced that Frontline Flex Pay, Powered by Wagestream is now available to all K-12 district employees.

Key Points: 
  • Malvern, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Frontline Education , a leading provider of administration software purpose-built for educators in K-12, today announced that Frontline Flex Pay, Powered by Wagestream is now available to all K-12 district employees.
  • Benefits of Frontline Flex Pay, Powered by Wagestream
    Previously available to only substitute teachers in K-12, Frontline Flex Pay, Powered by Wagestream, provides districts who opt-in to the service the ability to put a financial toolkit in the hands of all district employees – including instructional and non-instructional staff.
  • "Frontline Flex Pay Powered by Wagestream has been a game-changer for our district.
  • Implementing Flex Pay is seamless and adds minimal extra work to the district, all while bringing immediate value to both the district and its employees.